"I am glad that taking part in a trial might help others on their own cancer journey.”
A trial looking at chemotherapy for non small cell lung cancer
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This trial compared a chemotherapy combination called MIC with gemcitabine and carboplatin. It was for people with advanced non small cell lung cancer.
The aims of the trial were to find out
- If gemcitabine and carboplatin is better than MIC for advanced non small cell lung cancer
- More about the side effects and quality of life
Summary of results
The researchers found that gemcitabine and carboplatin is useful for treating advanced non small cell lung cancer.
The trial recruited 422 people. None of those who took part had had chemotherapy for non small lung cancer before. They had not had any radiotherapy for their cancer either. In this trial
- Half had MIC
- Half had gemcitabine and carboplatin
Most patients in both groups had 4 cycles of chemotherapy. The researchers analysed the results in 2005. They found around 4 in 10 people who had gemcitabine and carboplatin (40%) lived for more than one year compared to 3 in 10 people (30%) who had MIC.
The researchers also looked at quality of life. The people who had gemcitabine and carboplatin reported a better quality of life overall compared to the people who had MIC.
People who had gemcitabine and carboplatin had fewer problems with feeling or being sick, hair loss and constipation than people in the MIC group.
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Dr Robin Rudd
London Lung Cancer Group
National Institute for Health Research Cancer Research Network (NCRN)